nach oben

International Journal of Clinical Pharmacy

Erschienen in:

15.09.2023 | Review Article

Pharmacists’ contribution to benzodiazepine deprescribing in older outpatients: a systematic review and meta-analysis

verfasst von: Thiago Afonso Rodrigues Melo, Cleyton Oliveira Bezerra, Brígida Dias Fernandes, Inajara Rotta, Walleri Christini Torelli Reis, Patricia Melo Aguiar

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Consolidated and reliable evidence regarding the effectiveness of pharmacist interventions for deprescribing benzodiazepines in older outpatients is lacking.

Aim

This study evaluated and summarized the impact of pharmacist interventions on benzodiazepine deprescribing among older outpatients.

Method

A literature search was conducted until August 2022 in PubMed, PsycINFO, and the Cochrane Central Register of Controlled Trials databases. The review included randomized controlled trials that assessed the impact of pharmacist interventions on deprescribing benzodiazepine in older outpatients. Two independent investigators conducted the study selection, data extraction, and risk of bias assessment. Meta-analyses were conducted using random-effect models in the RStudio software.

Results

A total of 893 records were identified. Five studies, including 3,879 patients, met the inclusion criteria and were included in the systematic review. All five studies used health education as an intervention strategy, and three also conducted medication reviews. There was no evidence of the pharmacist’s authority to modify prescriptions during benzodiazepine deprescribing. One study was classified as having a low risk of bias, whereas the other had some concerns or a high risk of bias. Three studies were included in the meta-analysis and a significant impact of pharmacist interventions on benzodiazepines deprescribing rates in older outpatients was observed (RR = 2.75 [95%CI 1.29; 5.89]; p = 0.04; I² = 69%; low certainty of evidence).

Conclusion

Pharmacists may contribute to deprescribing benzodiazepines in older outpatients. Further studies are needed to increase the reliability of these findings.

PROSPERO registration number: CRD42022358563.

Nur mit Berechtigung zugänglich

McCarthy M, Mak S, Kaufmann CN, et al. Care coordination needs for deprescribing benzodiazepines and benzodiazepine receptor agonists. Res Social Adm Pharm. 2022;18(4):2691–4. https://doi.org/10.1016/j.sapharm.2021.06.025.CrossRefPubMed

Freire MBO, Da Silva BGC, Bertoldi AD, et al. Benzodiazepines utilization in Brazilian older adults: a population-based study. Rev Saude Publica. 2022;56:10. https://doi.org/10.11606/s1518-8787.2022056003740.CrossRefPubMedPubMedCentral

van Beek JH, Kirkwood TB, Bassingthwaighte JB, et al. Understanding the physiology of the ageing individual: computational modelling of changes in metabolism and endurance. Interface Focus. 2016;6(2):20150079. https://doi.org/10.1098/rsfs.2015.0079.CrossRefPubMedPubMedCentral

Airagnes G, Pelissolo A, Lavallée M, et al. Benzodiazepine misuse in the elderly: risk factors, consequences, and management. Curr Psych Rep. 2016;18(10):89. https://doi.org/10.1007/s11920-016-0727-9.CrossRef

Naloto DC, Lopes FC, Barberato Filho S, et al. Prescription of benzodiazepines for adults and older adults from a mental health clinic. Cien Saude Colet. 2016;21(4):1267–76. https://doi.org/10.1590/1413-81232015214.10292015.CrossRefPubMed

Fick DM, Semla TP, Steinman M, et al. American geriatrics society 2019 updated AGS beers criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94. https://doi.org/10.1111/jgs.15767.CrossRef

Ettcheto M, Olloquequi J, Sánchez-López E, et al. Benzodiazepines and related drugs as a risk factor in Alzheimer’s disease dementia. Front Aging Neurosci. 2020;11:344. https://doi.org/10.3389/fnagi.2019.00344.CrossRefPubMedPubMedCentral

Reeve E, Shakib S, Hendrix I, et al. Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol. 2014;78(4):738–47. https://doi.org/10.1111/bcp.12386.CrossRefPubMedPubMedCentral

Niznik JD, Collins BJ, Armistead LT, et al. Pharmacist interventions to deprescribe opioids and benzodiazepines in older adults: a rapid review. Res Social Adm Pharm. 2022;18(6):2913–21. https://doi.org/10.1016/j.sapharm.2021.07.012.CrossRefPubMed

10.

Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339–51.PubMedPubMedCentral

11.

Thillainadesan J, Gnjidic D, Green S, et al. Impact of deprescribing interventions in older hospitalised patients on prescribing and clinical outcomes: a systematic review of randomised trials. Drugs Aging. 2018;35(4):303–19. https://doi.org/10.1007/s40266-018-0536-4.CrossRefPubMed

12.

Bužančić I, Kummer I, Držaić M, et al. Community-based pharmacists’ role in deprescribing: a systematic review. Br J Clin Pharmacol. 2022;88(2):452–63. https://doi.org/10.1111/bcp.14947.CrossRefPubMed

13.

Ibrahim K, Cox NJ, Stevenson JM, et al. A systematic review of the evidence for deprescribing interventions among older people living with frailty. BMC Geriatr. 2021;21(1):258. https://doi.org/10.1186/s12877-021-02208-8.CrossRefPubMedPubMedCentral

14.

Higgins JPT, Thomas J, Chandler J, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook

15.

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906. https://doi.org/10.1136/bmj.n71.CrossRefPubMed

16.

Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https://doi.org/10.1186/s13643-016-0384-4.CrossRefPubMedPubMedCentral

17.

Dagnew SB, Binega Mekonnen G, Gebeye Zeleke E, et al. Clinical pharmacist intervention on drug-related problems among elderly patients admitted to medical wards of northwest Ethiopia comprehensive specialized hospitals: a multicenter prospective Observational Study. Biomed Res Int. 2022. https://doi.org/10.1155/2022/8742998.CrossRefPubMedPubMedCentral

18.

Higgins JPT, Savović J, Page MJ, et al. Assessing risk of bias in a randomized trial. Cochrane Handb Syst Rev Interv. 2019. https://doi.org/10.1002/9781119536604.ch8.CrossRef

19.

Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380–2. https://doi.org/10.1016/j.jclinepi.2010.09.011.CrossRefPubMed

20.

Schünemann H, Brozek J, Guyatt G, et al, editors (The GRADE Working Group) (2013) GRADE handbook for grading quality of evidence and strength of recommendations. Available from: http://www.guidelinedevelopment.org/handbook. Accessed 12 Jan 2023.

21.

Veroniki AA, Jackson D, Viechtbauer W, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7(1):55–79. https://doi.org/10.1002/jrsm.1164.CrossRefPubMed

22.

Schuller-Martínez B, Meza N, Pérez-Bracchiglione J, et al. Graphical representation of the body of the evidence: the essentials for understanding the evidence gap map approach. Medwave. 2021;21(3):e8164. https://doi.org/10.5867/medwave.2021.03.8164.CrossRefPubMed

23.

Ashworth N, Kain N, Wiebe D, et al. Reducing prescribing of benzodiazepines in older adults: a comparison of four physician-focused interventions by a medical regulatory authority. BMC Fam Pract. 2021;22(1):68. https://doi.org/10.1186/s12875-021-01415-x.CrossRefPubMedPubMedCentral

24.

Evrard P, Henrard S, Foulon V, et al. Benzodiazepine use and Deprescribing in Belgian nursing homes: results from the COME-ON study. J Am Geriatr Soc. 2020;68(12):2768–77. https://doi.org/10.1111/jgs.16751.CrossRefPubMed

25.

Navy HJ, Weffald L, Delate T, et al. Clinical pharmacist intervention to engage older adults in reducing use of alprazolam. Consult Pharm. 2018;33(12):711–22. https://doi.org/10.4140/TCP.n.2018.711.CrossRefPubMed

26.

Roberts MS, Stokes JA, King MA, et al. Outcomes of a randomized controlled trial of a clinical pharmacy intervention in 52 nursing homes. Br J Clin Pharmacol. 2001;51(3):257–65. https://doi.org/10.1046/j.1365-2125.2001.00347.x.CrossRefPubMedPubMedCentral

27.

Tannenbaum C, Martin P, Tamblyn R, et al. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890–8. https://doi.org/10.1001/jamainternmed.2014.949.CrossRefPubMed

28.

Hernández-Prats C, López-Pintor E, Lumbreras B, et al. Pharmacist-led intervention on the reduction of inappropriate medication use in patients with heart failure: a systematic review of randomized trials and non-randomized intervention studies. Res Social Adm Pharm. 2022;18(5):2748–56. https://doi.org/10.1016/j.sapharm.2021.06.023.CrossRefPubMed

29.

Balsom C, Pittman N, King R, et al. Impact of a pharmacist-administered deprescribing intervention on nursing home residents: a randomized controlled trial. Int J Clin Pharm. 2020;42(4):1153–67. https://doi.org/10.1007/s11096-020-01073-6.CrossRefPubMed

30.

Kua CH, Yeo CYY, Tan PC, et al. Association of deprescribing with reduction in mortality and hospitalization: a pragmatic stepped-wedge cluster-randomized controlled trial. J Am Med Dir Assoc. 2021;22(1):82–9. https://doi.org/10.1016/j.jamda.2020.03.012.CrossRefPubMed

31.

Lui E, Wintemute K, Muraca M, et al. Pharmacist-led sedative-hypnotic deprescribing in team-based primary care practice. Can Pharm J Ott. 2021;154(4):278–84. https://doi.org/10.1177/17151635211014918.CrossRefPubMedPubMedCentral

32.

Eide E, Schjøtt J. Assessing the effects of an intervention by a pharmacist on prescribing and administration of hypnotics in nursing homes. Pharm World Sci. 2001;23(6):227–31. https://doi.org/10.1023/a:1015142211348.CrossRefPubMed

33.

Stevenson DG, Decker SL, Dwyer LL, et al. Antipsychotic and benzodiazepine use among nursing home residents: findings from the 2004 National Nursing Home Survey. Am J Geriatr Psych. 2010;18(12):1078–92. https://doi.org/10.1097/JGP.0b013e3181d6c0c6.CrossRef

34.

Malagaris I, Mehta HB, Goodwin JS. Trends and variation in benzodiazepine use in nursing homes in the USA. Eur J Clin Pharmacol. 2022;78(3):489–96. https://doi.org/10.1007/s00228-021-03244-4.CrossRefPubMed

35.

Pollmann AS, Murphy AL, Bergman JC, et al. Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review. BMC Pharmacol Toxicol. 2015;16:19. https://doi.org/10.1186/s40360-015-0019-8.CrossRefPubMedPubMedCentral

36.

Ribeiro PRS, Schlindwein AD. Benzodiazepine deprescription strategies in chronic users: a systematic review. Fam Pract. 2021;38(5):684–93. https://doi.org/10.1093/fampra/cmab017.CrossRefPubMed

37.

Yariv H. The case of pharmacist prescribing policy in Israel. Isr J Health Policy Res. 2015;4:49. https://doi.org/10.1186/s13584-015-0045-4.CrossRefPubMedPubMedCentral

38.

Graham-Clarke E et al. Non-medical prescribing in the United Kingdom National Health Service: a systematic policy review. PLoS ONE. 2019;14(7):e0214630. https://doi.org/10.1371/journal.pone.0214630.CrossRefPubMedPubMedCentral

39.

Conselho Federal de Farmácia. (2013). Resolução CFF nº 586, de 29 de agosto de 2013. Regula a prescrição farmacêutica e dá outras Providências. Diário Oficial da União, 29. Retrieved from: https://www.semesp.org.br/wpcontent/uploads/2013/09/res_CFF_586-ok.pdf. Accessed 20 Jan 2023.

40.

Ramos DC et al. Pharmacist prescribing: a review of perceptions and attitudes of patients, pharmacists and other interested professionals. Ciencia saude coletiva. 2022;27:3531–46. https://doi.org/10.1590/1413-81232022279.19972021.CrossRefPubMed

41.

Mudge A, Radnedge K, Kasper K, et al. Effects of a pilot multidisciplinary clinic for frequent attending elderly patients on deprescribing. Aust Health Rev. 2016;40(1):86–91. https://doi.org/10.1071/AH14219.CrossRefPubMed

42.

Sakakibara M, Igarashi A, Takase Y, et al. Effects of prescription drug reduction on quality of life in community-dwelling patients with dementia. J Pharm Pharm Sci. 2015;18(5):705–12. https://doi.org/10.18433/j37p5x.CrossRefPubMed

43.

Cross AJ, George J, Woodward MC, et al. Deprescribing potentially inappropriate medications in memory clinic patients (DePIMM): a feasibility study. Res Social Adm Pharm. 2020;16(10):1392–7. https://doi.org/10.1016/j.sapharm.2020.01.010.CrossRefPubMed

44.

Evrard P, Pétein C, Beuscart JB, et al. Barriers and enablers for deprescribing benzodiazepine receptor agonists in older adults: a systematic review of qualitative and quantitative studies using the theoretical domains framework. Implement Sci. 2022;17(1):17–41. https://doi.org/10.1186/s13012-022-01206-7.CrossRef

45.

Carr F, Tian P, Chow J, et al. Deprescribing benzodiazepines among hospitalised older adults: quality improvement initiative. BMJ Open Qual. 2019;8(3):1–8. https://doi.org/10.1136/bmjoq-2018-000539.CrossRef

Titel: Pharmacists’ contribution to benzodiazepine deprescribing in older outpatients: a systematic review and meta-analysis
verfasst von: Thiago Afonso Rodrigues Melo
Cleyton Oliveira Bezerra
Brígida Dias Fernandes
Inajara Rotta
Walleri Christini Torelli Reis
Patricia Melo Aguiar
Publikationsdatum: 15.09.2023
Verlag: Springer International Publishing
Erschienen in: International Journal of Clinical Pharmacy / Ausgabe 5/2023
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI: https://doi.org/10.1007/s11096-023-01637-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Pharmacists’ contribution to benzodiazepine deprescribing in older outpatients: a systematic review and meta-analysis